Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update

Thompson, Ian M.; Thrasher, J. Brantley; Aus, Gunnar; Burnett, Arthur L.; Canby-Hagino, Edith; Cookson, Michael S.; D’Amico, Anthony V.; Dmochowski, Roger R.; Eton, David T.; Forman, Jeffrey D.; Goldenberg, S. Larry; Hernández, Javier; Higano, Celestia S.; Kraus, Stephen R.; Moul, Judd W.; Tangen, Catherine M.

doi:10.1016/j.juro.2007.03.003

Cited by 957 publications

(719 citation statements)

References 105 publications

Supporting

Mentioning

691

Contrasting

Unclassified

Order By: Relevance

“…37,38 Consequently, treatment recommendations are predicated on whether the patient can be expected to have a 10-year to 15-year life expectancy. 2,3 Although competing risks of mortality for men with localized prostate cancer are well recognized, 38,39 clinicians often poorly estimate life expectancy. 6,7 Adjusting life tables for comorbidity scores obtained from the SEER-Medicare database improves non-cancer survival estimates for recently diagnosed cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…37,44 Treatment recommendations have changed over the past few decades, and more men with localized prostate cancers are being encouraged to consider observation. 2 This could mean higher prostate-cancer mortality rates, though that would differentially impact men reporting excellent health rather than poor health, because the latter would not 45 and the proportion of prostate cancer deaths was quite small. Additionally, subjects completed the initial survey 6 months after diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…1 Consequently, guidelines suggest observation (watchful waiting) for men with limited life expectancies (< 10 years) who are diagnosed with localized prostate cancer, because they are unlikely to realize any survival benefit from treatment. 2,3 However, studies consistently show that men with limited life expectancy often receive aggressive treatment for even low-risk, localized cancers. 4,5 One explanation is that physicians have difficulty accurately estimating the effect of competing mortality risks on life expectancy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study

et al. 2015

View full text Add to dashboard Cite

BACKGROUND: Guidelines recommend against treating localized prostate cancer (PCa) in men with a greater than10-year life expectancy. However, physicians have difficulty accurately estimating life expectancy. OBJECTIVE: We used data from a population-based observational study to develop a nomogram to estimate long-term other-cause mortality based on self-reported health status (SRHS), race/ethnicity, and age at diagnosis. DESIGN: This was an observational study. SUBJECTS: Men diagnosed with localized PCa from October 1994 through October 1995 participated in the study. MAIN MEASURES: Initial measures obtained 6 months after diagnosis included sociodemographic and tumor characteristics, treatment, and a single item on the SRHS, with response options ranging from excellent to poor. We used Surveillance, Epidemiology, and End-Results program data to determine date and cause of death through December 2010. We estimated other-cause mortality with proportional hazards survival analyses, accounting for competing risks. KEY RESULTS: We evaluated 2,695 men, of whom 74 % underwent aggressive therapy (surgery or radiotherapy). At the initial survey, 18 % reported excellent (E), 36 % very good (VG), 31 % good (G), and 15 % fair/poor (F/P) health. Healthier men were younger, and more likely to be white, better educated, and to undergo surgery. At follow-up, 44 % of the cohort had died; 78 % of deaths were from causes other than PCa. SRHS predicted other-cause mortality; for men reporting E, VG, G, F/P health, the cumulative incidences of other-cause mortality were 20 %, 29 %, 40 %, and 53 %, respectively, p<0.001. Compared to a reference of excellent SRHS, multivariable hazard ratios (95 % CI) for other-cause mortality for men reporting VG, G, and F/P health were 1.22 (0

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[19][20] Radical retropubic prostatectomy, 21 laparoscopic radical prostatectomy, 22 cryosurgery, 22 external beam radiation therapy, 23 brachytherapy 24 and active surveillance 22 have been reported for HIVpositive men with localized PCa and found to be generally safe and efficacious in the short term. 17 The oncological risk posed by PCa in the HIV-positive cohort did not differ significantly from the non-HIVpositive cohort, based on a variety of prognostic data including PSA value, clinical tumor stage, biopsy Gleason sum, D'Amico risk stratification and pathological tumor grade or stage.…”

Section: Ralp In Men With Hiv Jl Silberstein Et Almentioning

confidence: 99%

Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus

Silberstein

Parsons

Palazzi-Churas

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The aim of this study is to evaluate the outcomes of robot-assisted laparoscopic prostatectomy (RALP) in prostate cancer (PCa) patients with human immunodeficiency virus (HIV). This is a prospective cohort study of HIV patients undergoing RALP, comparing the demographics, tumor characteristics, complications, and short-term oncological outcomes of HIV-positive men to HIV-negative men using univariate (v 2 , Mann-Whitney test) and multivariable (logistic regression) analyses. From 2007 to 2010, 298 men underwent RALP, 8 of whom were known to be HIV positive. Preoperatively, all eight were taking highly active antiretroviral therapy (HAART) and had undetectable viral loads (o50); mean CD4 count was 634 cells per mm 3 . HIV-positive men were younger (54 versus 62 years, P ¼ 0.010) and less likely to be white (P ¼ 0.007). There were no significant differences between groups with respect to clinical staging, pathological and oncological outcomes or most complication rates. However, the prevalence of perioperative transfusions (P ¼ 0.031) and ileus (P ¼ 0.021) were higher in HIV-positive patients. HIV remained significantly associated with risk of transfusion after adjustment for age, race, Gleason sum and clinical T stage (P ¼ 0.002). After a median of 2.6 (range 0.03-19.2) months of follow-up, PSA remained undetectable in all eight HIV patients. These data suggest that RALP is safe for, and demonstrates short-term oncological efficacy in, HIV-positive patients with PCa.

show abstract

“…The American Urological Association guidelines on management of clinically localized PC consider AS a viable monotherapy for clinically localized low-risk PC, along with other options including TP and radiation therapy. 16 Although the ideal protocol for monitoring a patient on AS is still being defined, the National Comprehensive Cancer Network guidelines recommend a stringent protocol with a PSA as often as 3 months and at least 6 months, DRE every 6 months and at least 12 months, and needle biopsy as often as annually for patients with a life expectancy of 410 years and less often for patients with o10 years. 17 Hence, it is apparent that AS relies heavily on a long and consistent patientphysician interaction.…”

Section: Discussionmentioning

confidence: 99%

Comparison of urologist reimbursement for managing patients with low-risk prostate cancer by active surveillance versus total prostatectomy

Manoharan

Eldefrawy

Katkoori

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update

Cited by 957 publications

References 105 publications

Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study

Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study

Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus

Comparison of urologist reimbursement for managing patients with low-risk prostate cancer by active surveillance versus total prostatectomy

Contact Info

Product

Resources

About